Vaccination is among the greatest public health achievements of the 20th century, banishing feared diseases from the lives of those fortunate enough to be immunized. But 1.5 million people continue to die each year from vaccine-preventable diseases.
The Global Vaccine Action Plan
The Global Vaccine Action Plan (GVAP) is a framework to end that inequity and extend the benefits of vaccination to everyone, regardless of where they are born.
Novartis today announced that it has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.